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A Paradigm Shift and New Therapeutic 
Options for the Metabolic Syndrome
Christodoulos Flordellis, ÌD, Ph.D.
The metabolic syndrome, characterized by obesity, dyslipidemia, insulin resistance 
and hypertension, increases the risk of cardiovascular morbidity and mortality. Most 
current views on the pathogenesis of the metabolic syndrome and its existing treatments 
have been dominated by a glucocentric approach: the glycemic response to insulin 
is suboptimal, with dire metabolic consequences. Such consequences are compen-
satory hyperinsulinemia, â cell glucotoxicity and lipotoxicity and the deposition of 
amyloid in pancreatic islets, with concomitant inflammation, endothelial dysfunction, 
a procoagulant state and dyslipidemia. In addition, these views have been applied on 
the premise that effector molecules involved in disease pathogenesis or response to 
therapy are invariant across the population. However, most current therapies have 
limited efficacy and limited tolerability. 
In recent years, the convergence of evidence from several studies has resulted in 
a major shift both in the understanding of the pathophysiology and the treatment op-
tions for this disease. This is based on a unified ‘lipotoxicity’ hypothesis, according to 
which metabolic syndrome and type 2 diabetes mellitus can be caused by the ectopic 
accumulation of triglycerides and long-chain fatty acids in liver, muscle and pancreatic 
islets. Similar lipid changes in selective hypothalamic neurons regulate insulin action 
and glucose homeostasis, in addition to food intake and body weight. This lipocentric 
approach is integrated with the analysis of inflammatory reactions associated with end-
organ damage, including that in the vascular wall. The integration of inflammatory and 
metabolic mechanisms in obesity is based on the functional overlap of macrophages 
and adipocytes. The latter reflects the plasticity of macrophage and pre-adipocyte. 
Adipocytes produce inflammatory “macrophage” proteins such as tumor necrosis 
factor á (TNF-á), interleukin 6 (IL-6) and metaloproteinases (MMPs). In addition 
adipokines, such as adiponectin, resistin and visfatin have immunological activity 
along with metabolic functions. Moreover, lipids themselves exert inflammatory and 
metabolic actions through lipid-targeted pathways via nuclear receptors. Meanwhile 
macrophages express peroxisome proliferator-activated receptor ã (PPARã).
Transcription factors and coactivators, including PPARã coactivator-1 are cru-
cial in mediating insulin resistance and accelerating vascular wall inflammation, and 
represent promising therapeutic targets. New pharmacological strategies include dual 
PPARá/ã agonists, drugs with pleiotropic effects or combination therapies.
Finally, the application of genomic and proteomic methodologies in animal models 
of diabetes, and in serum and tissues from normal individuals and patients with type 
2 diabetes mellitus, has identified clusters of genes and proteins that might contribute 
to cardinal aspects of this disease such as insulin resistance, â cell dysfunction and 
vascular wall damage. The new integrated view of the metabolic syndrome takes into 
account the genetic differences among individuals when the clinical heterogeneity of 
the clinical phenotypes or variation of the response to therapy is considered. 
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